The U.S. Food and Drug Administration (FDA) will hold a two-day public workshop in April to discuss the potential safety risks of e-cigarettes, according to The Hill. The announcement comes on the heels of the agency’s latest report documenting the rise in the number of e-cigarette explosions, as reported by Beasley Allen.
The workshops will be part of the FDA’s efforts to increase oversight of the electronic smoking industry. Last August, the agency “finalized a rule extending its regulatory authority to all tobacco products, including e-cigarettes, cigars and hookah and pipe tobacco, as part of its goal to improve public health.” Its end goal is to better protect U.S. residents.
The announcement also comes days after another U.S. Senator called for federal action to address the “dangerous devices.” In a press release posted on Politicalnews.me, U.S. Senator Richard Blumenthal (D-CT) called on the FDA and the U.S. Consumer Product Safety Commission (CPSC) to better protect consumers from exploding e-cigarettes. He was prompted to act after a constituent became one of the latest victims of exploding e-cigarettes.
Blumenthal wants defective products recalled and clear safety standards for future devices along with the lithium-ion batteries that power them. According to Righting Injustice, U.S. Senator Charles Schumer (D-NY) also demanded similar action to address the defective devices.
The explosions have been linked to overheating of the lithium-ion batteries that power electronic smoking devices. The lithium-ion batteries have caused similar problems in hoverboards and various smartphones.
Blumenthal issued a similar call to action in a letter to major U.S. airlines, demanding that they voluntarily follow the lead of the U.S. Department of Transportation (DOT) and expand the ban of electronic smoking devices, issued early in 2016, to include the passenger cabin as well as checked baggage.
* * *
If you would like more information about lithium-ion batteries, you can contact Will Sutton, a lawyer in Toxic Torts Section. He can be reached at 800-898-2034 or by email at William.Sutton@beasleyallen.com.
U.S. Food and Drug Administration